T. Rowe Price Associates’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $196K | Buy |
84,603
+10,578
| +14% | +$24.5K | ﹤0.01% | 2721 |
|
|
2025
Q1 | $103K | Buy |
74,025
+8,694
| +13% | +$12.1K | ﹤0.01% | 2814 |
|
|
2024
Q4 | $114K | Buy |
65,331
+5,612
| +9% | +$9.79K | ﹤0.01% | 2803 |
|
|
2024
Q3 | $121K | Sell |
59,719
-1,216,859
| -95% | -$2.47M | ﹤0.01% | 2783 |
|
|
2024
Q2 | $2.86M | Buy |
1,276,578
+177,249
| +16% | +$397K | ﹤0.01% | 1411 |
|
|
2024
Q1 | $3.16M | Sell |
1,099,329
-128,004
| -10% | -$367K | ﹤0.01% | 1366 |
|
|
2023
Q4 | $2.17M | Sell |
1,227,333
-20,138
| -2% | -$35.7K | ﹤0.01% | 1481 |
|
|
2023
Q3 | $3.94M | Buy |
+1,247,471
| New | +$3.94M | ﹤0.01% | 1228 |
|